12/4
07:34 am
nbp
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
Low
Report
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
12/3
07:30 pm
nbp
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
Medium
Report
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
11/21
12:46 am
nbp
NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
Medium
Report
NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
11/20
08:00 pm
nbp
NovaBridge’s Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
Medium
Report
NovaBridge’s Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
10/30
04:15 am
nbp
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries
Medium
Report
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries
10/29
06:27 pm
nbp
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries
Low
Report
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries